Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study

Inclusion Criteria: * A diagnosis of cancer, other than basal-cell or squamous-cell carcinoma of the skin, within six months before enrollment. Any treatment for cancer within the previous six months, or recurrent or metastatic cancer. * Objectively verified venous thrombosis * Informed consent Exclusion Criteria: * Anticoagulant therapy prior to trial entry for \> 96 hours * Severe thrombocytopenia (platelets \<50·109/L) * Severe renal failure - creatinine clearance \<30 ml/min * The patients will be treated with catheter based thrombolysis for deep venous thrombosis or systemic thrombolysis for severe pulmonary embolism * Pregnancy or breastfeeding. * Childbearing potential without proper contraceptive measures * Drug abuse or mental disease that may interfere with treatment and follow-up. * Severe malabsorption so that oral treatment are expected to have reduced effect * Mechanical heart valves * Known allergy to apixaban * Active bleeding or severe risk of bleeding so that the risk of bleeding is considered a greater danger than the risk of not treating the venous thrombosis * Clinically significant liver disease (e.g., acute hepatitis, chronic active hepatitis, or cirrhosis) * Concomitant use of strong cytochrome P-450 3A4 inhibitors (e.g., human immunodeficiency virus protease inhibitors or systemic ketoconazole, voriconazole or posaconazole) or inducers (e.g., rifampicin, carbamazepine, or phenytoin). Fluconazol is allowed.